Archive

Latest California Healthline Stories

Podcast: KHN’s ‘What The Health?’ A Detour On A Smoking Off-Ramp

In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administration’s latest actions to address teenagers’ use of e-cigarettes, Arkansas’ Medicaid work requirements and news about the uninsured from the latest federal Census report.

California’s Uninsured Rate Declined Last Year Despite Federal Efforts To Roll Back ACA

The percentage of people without insurance in California continued its decline in 2017, despite Republican efforts in Washington, D.C. to roll back the Affordable Care Act. The uninsured rate now stands 10 percentage points below its level in 2013 — the year before the coverage expanding provisions of the federal health law took effect, according to a report by the U.S. Census Bureau.

Confusion Leaves Low-Income Children In Health Care Limbo

Some low-income children in California are not getting medical, dental and mental health treatments to which they are entitled under federal law. Legal aid advocates blame a confusing disconnect between state and federal law, and a bill to address the problem is awaiting Gov. Jerry Brown’s approval — or veto.

As Treatable As Diabetes? Lawmakers Push New Ways To Stem Opioid Addiction

California lawmakers approved 14 measures to address the opioid crisis, including one that requires health plans to cover medication-based treatments for opioid addiction without requiring pre-authorization. Gov. Jerry Brown has until the end of September to approve or reject the proposals.

The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide

Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.